Suppr超能文献

阿尔茨海默病治疗的前沿。

Frontiers in Alzheimer's disease therapeutics.

机构信息

Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.

出版信息

Ther Adv Chronic Dis. 2011 Jan 1;2(1):9-23. doi: 10.1177/2040622310382817.

Abstract

Alzheimer disease (AD) is a progressive neurodegenerative disease which begins with insidious deterioration of higher cognition and progresses to severe dementia. Clinical symptoms typically involve impairment of memory and at least one other cognitive domain. Because of the exponential increase in the incidence of AD with age, the aging population across the world has seen a congruous increase AD, emphasizing the importance of disease altering therapy. Current therapeutics on the market, including cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists, provide symptomatic relief but do not alter progression of the disease. Therefore, progress in the areas of prevention and disease modification may be of critical interest. In this review, we summarize novel AD therapeutics that are currently being explored, and also mechanisms of action of specific drugs within the context of current knowledge of AD pathologic pathways.

摘要

阿尔茨海默病(AD)是一种进行性神经退行性疾病,始于高级认知功能的隐匿性恶化,并进展为严重痴呆。临床症状通常包括记忆障碍和至少其他一个认知领域的损害。由于 AD 的发病率随年龄呈指数增长,全球老龄化人口中 AD 的发病率相应增加,这强调了改变疾病治疗方法的重要性。目前市场上的治疗方法,包括胆碱酯酶抑制剂和 N-甲基-D-天冬氨酸受体拮抗剂,仅能提供症状缓解,而不能改变疾病的进展。因此,预防和疾病修饰领域的进展可能具有重要意义。在这篇综述中,我们总结了目前正在探索的新型 AD 治疗方法,并根据 AD 病理途径的现有知识,总结了特定药物的作用机制。

相似文献

1
Frontiers in Alzheimer's disease therapeutics.
Ther Adv Chronic Dis. 2011 Jan 1;2(1):9-23. doi: 10.1177/2040622310382817.
2
Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
Pharmacol Ther. 2012 Apr;134(1):8-25. doi: 10.1016/j.pharmthera.2011.12.002. Epub 2011 Dec 16.
3
Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Curr Alzheimer Res. 2019;16(5):418-452. doi: 10.2174/1567205016666190321163438.
4
Alzheimer's Disease and Its Potential Alternative Therapeutics.
J Alzheimers Dis Parkinsonism. 2019;9(5). doi: 10.4172/2161-0460.1000477. Epub 2019 Sep 13.
5
Exploring Alzheimer's disease treatment: Established therapies and novel strategies for future care.
Eur J Pharmacol. 2025 Jul 5;998:177520. doi: 10.1016/j.ejphar.2025.177520. Epub 2025 Mar 15.
7
8
Carbamate as a potential anti-Alzheimer's pharmacophore: A review.
Drug Dev Res. 2023 Dec;84(8):1624-1651. doi: 10.1002/ddr.22113. Epub 2023 Sep 11.
9
A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
Curr Pharm Des. 2023;29(43):3428-3441. doi: 10.2174/0113816128264355231121064704.
10
Mechanism of Metal Complexes in Alzheimer's Disease.
Int J Mol Sci. 2024 Nov 5;25(22):11873. doi: 10.3390/ijms252211873.

引用本文的文献

2
Molecular interaction of human acetylcholinesterase with -tephrostachin and derivatives for Alzheimer's disease.
Heliyon. 2020 Sep 14;6(9):e04930. doi: 10.1016/j.heliyon.2020.e04930. eCollection 2020 Sep.
5
Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.
Cell Mol Life Sci. 2017 Nov;74(22):4159-4169. doi: 10.1007/s00018-017-2574-1. Epub 2017 Jun 20.
6
Degenerative alterations in noradrenergic neurons of the locus coeruleus in Alzheimer's disease.
Neural Regen Res. 2013 Aug 25;8(24):2249-55. doi: 10.3969/j.issn.1673-5374.2013.24.004.
7
Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice.
Front Aging Neurosci. 2014 Jul 23;6:162. doi: 10.3389/fnagi.2014.00162. eCollection 2014.
8
Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease.
PLoS One. 2013;8(2):e56870. doi: 10.1371/journal.pone.0056870. Epub 2013 Feb 18.
9
β amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease mice.
Neurobiol Aging. 2013 Jun;34(6):1632-43. doi: 10.1016/j.neurobiolaging.2012.12.013. Epub 2013 Jan 18.

本文引用的文献

1
Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):140-8. doi: 10.2174/187152710791011991.
2
Sertraline for the treatment of depression in Alzheimer disease.
Am J Geriatr Psychiatry. 2010 Feb;18(2):136-45. doi: 10.1097/JGP.0b013e3181c796eb.
3
Oxidative stress in the progression of Alzheimer disease in the frontal cortex.
J Neuropathol Exp Neurol. 2010 Feb;69(2):155-67. doi: 10.1097/NEN.0b013e3181cb5af4.
5
Review: cell cycle aberrations and neurodegeneration.
Neuropathol Appl Neurobiol. 2010 Apr;36(2):157-63. doi: 10.1111/j.1365-2990.2010.01064.x. Epub 2010 Jan 6.
6
Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease.
Neurobiol Dis. 2010 Mar;37(3):731-7. doi: 10.1016/j.nbd.2009.12.012. Epub 2009 Dec 23.
8
Promising strategies for the prevention of dementia.
Arch Neurol. 2009 Oct;66(10):1210-5. doi: 10.1001/archneurol.2009.201.
9
Abnormal mitochondrial dynamics and neurodegenerative diseases.
Biochim Biophys Acta. 2010 Jan;1802(1):135-42. doi: 10.1016/j.bbadis.2009.09.013. Epub 2009 Sep 30.
10
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Nat Rev Drug Discov. 2009 Oct;8(10):783-93. doi: 10.1038/nrd2959.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验